Targeting a common collaborator in cancer development Article uri icon

Overview

MeSH Major

  • Antibiotics, Antineoplastic
  • Cell Line, Tumor
  • Doxorubicin
  • Indazoles
  • Neoplasms
  • Sulfonamides

abstract

  • In this issue of Science Translational Medicine, Wallin et al. have identified a subset of breast and ovarian cancer cell lines that show synergistic response to the combination of doxorubicin and GDC-0941, a class IA phosphatidylinositol 3-kinase (PI3K) inhibitor. Here, we discuss the potential implications of these data on the clinical development of PI3K pathway inhibitors as cancer therapeutics.

publication date

  • September 8, 2010

Research

keywords

  • Article

Identity

Digital Object Identifier (DOI)

  • 10.1126/scitranslmed.3001251

Additional Document Info

start page

  • 48ps45

volume

  • 2

number

  • 48